NeuroVive announces that the clinical study CiPRICS will be presented at the Swedish Thorax meeting in October 2016

Lund, Sweden, August 30, 2016 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the clinical study CiPRICS will be presented at the Swedish Thorax meeting in Malmö in October, 2016. Data collection and an initial results analysis is estimated to be completed at this time point.

Ass Prof. Henrik Bjursten M.D. Ph.D., Dept. of Cardiothoracic Surgery, Anesthesia and Intensive Care at Skåne University Hospital in Lund, will give an oral presentation with the title ”Ciclosporin to Protect Renal function In Cardiac Surgery (CiPRICS). A Double Blind, Randomised, Placebo Controlled, Proof of Concept Study” at the Swedish Thorax meeting in Malmö on October 13, 2016.

For further information about the program, please the conference web site:


The CiPRICS study (Ciclosporin to Protect Renal Function In Cardiac Surgery) is a double-blind, randomized and placebo-controlled explorative Phase II study that investigates NeuroVive’s drug candidate CicloMulsion as treatment for acute kidney injury (AKI). The patients are being treated with CicloMulsion or placebo in connection with coronary artery bypass surgery (CABG) at the Department of Cardiothoracic Surgery at Skåne University Hospital in Lund, Sweden. The study is investigator-initiated and performed by Skåne University Hospital with support from NeuroVive. More information about the study is published in the public database

About NeuroVive

NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive’s business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe.

NeuroVive’s portfolio consists of two clinical projects, one in acute kidney injury (CicloMulsion®) and one in traumatic brain injury (NeuroSTAT®). The candidate drug NeuroSTAT has orphan drug designation in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in the CHIC study. CicloMulsion is being evaluated in an on-going study, CiPRICS, in acute kidney injury during major surgery. Furthermore, the R&D portfolio consists of two late stage discovery programs and one compound in preclinical development.

NeuroVive is listed on Nasdaq Stockholm, Sweden, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC Markets Group Inc market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTCQX Best Market.

For investor relations and media questions, please contact:  
Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or 

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)  

This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11:30 a.m. CEST on August 30, 2016.